The Essex University MD Scheme The Steady State Origins.

Slides:

Advertisements

Similar presentations

Health, Disease and Survival The Essex Biomedical Sciences Institute Essex Biomedical Sciences Institute Dr Beverley Wilkinson Department of Biological.

Advertisements

New Zealand Regional Cancer Networks Improved cancer control through increased regional collaboration.

Reinventing Cancer Support Ciarán Devane Chief Executive.

© 2014 Boston Healthcare Associates, Inc. | 1 Florida Blue Cross, the largest commercial payer in Florida, has established an “Oncology ACO” that is one.

Living with and beyond treatment for cancer – the challenge for secondary care Nigel Acheson Medical Director Peninsula Cancer Network.

Prostate cancer: early detection, monitoring and prognosis: Essex Biomedical Sciences Institute (EBSI) Elena Klenova, University of Essex the search for.

23 hour surgery Beth Jackson Senior Clinical Nurse Specialist Breast Unit The Royal Marsden Hospital NHS Foundation Trust.

S Strong 1,2, NS Blencowe 1,2,T Fox 1, C Reid 3, T Crosby 4, H.Ford 5, J M Blazeby 1,2 1 School of Social and Community Medicine, Canynge Hall, University.

Caroline Belchamber Senior Oncology Physiotherapist

Biomarker studies in advanced breast cancer Dr Phil Murray (CHUFT) & Dr Dawn Farrar (UOE)

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

Breast Cancer: Follow up and Management of recurrence Carol Marquez, M.D. Associate Professor Department of Radiation Medicine OHSU.

By Rachel, Xiao Xia, Helen. Introduction Definition Symptoms Causes Prevention Treatment Prognosis Statistics Conclusion.

Breast Cancer Surgery Challenging Preconceptions Hamish Brown Consultant Breast and General Surgeon Sandwell and West Birmingham Hospitals NHS Trust

Eleni Galani Medical Oncologist

Driving the Transition to Individualized Cancer Treatment by Addressing Critical Questions 1 Do I need surgery? chemotherapy? radiation? INVASIVE BREAST.

Biomarkers Andrew McNaught BME. What is a biomarker? Gives us the ability to analyze organ function, diagnose diseases in a non-invasive way. Biomarkers.

How are we doing? Quality in Breast Cancer Care Dr Michelle Goecke Surgical Oncology Network Update October 18, 2014.

"Local initiatives developing exercise programmes for cancer patients" Louise Ballagher Senior Physiotherapist Oncology and Haematology RD&E Foundation.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

1 Franchise of CGN Research Labs Pvt.Ltd, India. CGN Research Labs LLC, USA.

Role of religion and spirituality in cancer coping among African Americans: A qualitative examination Cheryl L. Holt 1, PhD; Emily Schulz 1, PhD; Lee Caplan.

Role of Biomarkers in Management of Prostate Cancer Dr. Angela Amayo Specialist Pathologist 13 th April 2012.

OF COLOREATAL CANCER USING SEROLOGIC TUMOR MARKERS DIAGNOSIS & MANAGEMENT.

Routine PSA: Evaluating the Evidence Sheldon Greenfield, MD Health Policy Research Institute University of California, Irvine October 23, 2012.

PET in Colorectal Cancer. Indications for FDG PET Rising marker, (-) CT/MRI Nonspecific findings on CT/MRI, recurrence or post treatment changes? Known.

When will the diagnosis of Circulating tumor cells (CTC) help to patients? Martin Pešta, Ondřej Topolčan Department of Internal Medicine II, Faculty of.

File #1 Table of Contents Introduction Presenter’s Notes Oncology Rehabilitation: Web-based Learning for Physical Therapists Who Provide Rehabilitation.

Katie Ludwig FY1.   50, 285 New cases of breast cancer  11, 716 deaths  78% - 10 year survival rates  27% preventable cases  Source:

Analysis of Patient Experience of Cancer Care Pathway within Merseyside & Cheshire Produced by Merseyside and Cheshire Cancer Network Presented: November.

“Best” Practices In Outcomes Research ISW 2013 Helsinki, Finland Christine Laronga MD FACS Comprehensive Breast Program H. Lee Moffitt Cancer Center.

Chester Ellesmere Port & Neston Rural Making sure you get the healthcare you need West Cheshire CCG Strategy Dr Andy McAlavey Medical Director West Cheshire.

The Use of Predictive Biomarkers in Clinical Trial Design Richard Simon, D.Sc. Chief, Biometric Research Branch National Cancer Institute

Potential therapeutic target & predictive biomarker Oncogenic IGFBP2 Sonya Song ( 宋韦 ) Beijing Shijitan Hospital Department of Oncology The Capital Medical.

Poster Title ABSTRACT #59 Cell cycle progression genes differentiate indolent from aggressive prostate cancer. Steven Stone 1 Jack Cuzick 2, Julia Reid.

Tumor Markers American cancer society British Journal of Cancer By B.Heidari.

DEBIRI TACE Patterns and Predictors of Response

Blood and Tissue Based Molecular Signatures in Predicting Prostate Cancer Progression Tarek A. Bismar, MD Professor, University of Calgary Departments.

Establishment and verification of miRNAs expression molecules for breast cancer and its distant metastasis Yanhong Gao Associate Professor Department of.

Elena Klenova CTCF and BORIS in normal development, epigenetics and tumourigenesis Areas of research: Molecular Oncology Gene regulation Translational.

Facilitating tissue collection for translational research Jane Rogan Business Manager.

Florida Cancer Plan Phil Roland, MD FACS FACOG Florida State Chair A Commission on Cancer.

The Cancer Registry of Norway Jan F Nygård Head of the IT-department.

Univariate Analyses Treatment Outcome And Patterns Of Relapse Following Adjuvant Carboplatin For Stage I Testicular Seminoma: Results From a 17 Year UK.

Troponin By Julie Moore C Dt204/2.

New Patient telephone follow up clinic. Introduction North Tees and Hartlepool NHS Foundation Trust treat patients across two sites. We currently administer.

Introductions Dr Emma Bowers Training Coordinator Talk about: NTC Blended learning Master’s Programme Joe Spoor 1 st year STP trainee Lauren Slater 1 st.

Novel blood and tissue Biomarkers for Breast and Prostate Cancers

Evolution-informed Modeling discover biomarkers for precision oncology Li Liu, M.D. August 22, 2016.

Common pitfall in Oncology Luangyot Thongthieang, MD MEDICAL ONCOLOGY UNIT INTERNAL MEDICINE, KHONKAEN HOSPITAL.

Tumor markers 1111.

Omega Best Cancer Hospital - India

The third Annual Conference On Gynecologic Oncology and Prevention Oncology July 20-21, 2017 Chicago, Illinoid USA PPGYNO1 Poster Title.

SURGICAL ONCOLOGY AND TUMOR MARKERS

GENETIC BIOMARKERS.

Institute of Oncology, Riga, Latvia

Clinical evaluation of UHC for cancer

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Oncology for Family Medicine Residents:

Circulating Melanoma Cells (CMCs) in Mucosal and Uveal Melanomas

CONVERSATIONS ON PROSTATE CANCER

سرطان الثدي Breast Cancer

Neuropathic Symptoms and Their Risk Factors in Medical Oncology Outpatients With Colorectal vs. Breast, Lung, or Prostate Cancer: Results From a Prospective.

Volume 53, Issue 4, Pages (April 2008)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Isaac M. Bromberg, MD Journal of Pain and Symptom Management

SWAG SSG Brain Cancer Meeting

Three-year DFS rates of T x N subsets of the ACTS-CC trial and IDEA study.19 Annotation: definitions of DFS in ACTS-CC and IDEA were different. Three-year.

Living With & Beyond Cancer (Personalised Care): SWAG Colorectal CAG Update 5th June 2019 Catherine Neck, Macmillan Cancer Rehabilitation/ LWBC Lead On.

Representativeness of linked cancer registry and dispensed prescription data as compared with cancer registry data alone, by key patient and tumour characteristics.

Presentation transcript:

The Essex University MD Scheme The Steady State Origins

Elena KlenovaJohn NortonSimon MarshTan Arulampalan Phil MurrayNeil RothnieAnne RobinsonAndrew Poynter Chris ScraseSiobhan HartFrederick GayMark Jorge Tony ElstonPaul KellyOkansa HoileLinda Fox David ToddDebo AdemokumMetodi Metodiev Murray GriffinValerie GladwellRalph Beneke Terry McGenityPaul BromleyGavin Sandercock Dominic MicklewrightCorinne Whitby

Breast cancerColorectal cancerNeuropsychology Haematology Prostate cancer Sports and exercise medicine Physiotherapy Cardiorespiratory physiology Cardiac rehabilitation Back pain Microbiology

Southend University Hospital NHS Foundation Trust Colchester Hospitals University NHS Foundation Trust Ipswich Hospital NHS Trust

How to set up an MD programme Desire Drive Stubbornness Imperative

Project Money Doctor

Right person:Clinical experience Money:University fees Salary Enterprise(!) What you need:

Colorectal Research Fellows: James Wright Nicholas Ward Christopher Liao Nikhil Pawa Justine Lawrence Breast Research Fellows Naresh Pore Adhip Mandal Anu Apote

So, what’s the point? The Doctor The Hospital The University Me

ASSESSMENT OF THE UTILITY OF BORIS PROTEIN AS A BLOOD AND TISSUE BIOMARKER OF BREAST CANCER. MD Thesis

Papers The potential of BORS detected in the leukocytes of breast cancer patients As an early marker of tumourigenesis Human Cancer Biology BORIS a paralogue of the transcription factor, CTFC, is aberrantly expressed In breast tumours British Journal of Cancer

Abstracts BORIS (Brother of Regulator of Imprinting Sites) as a possible new blood marker for breast cancer European Journal of Surgical Oncology BORIS- A true indicator of clear margins and predictor of local recurrence? European Journal of Surgical Oncology BORIS as a possible new Blood Marker for Breast Cancer. European Journal of Surgical Oncology

Posters BORIS: a new potential peripheral biomarker for breast cancer; evaluation of its role in surveillance, diagnosis and prognosis. San Diego, California Significance of BORIS (Brother of Regulator of Imprinted Sites) expression to chemotherapy in breast cancer patients Miami, Florida BORIS- A true indicator of clear margins and predictor of local recurrence? Miami, Florida BORIS as a possible new Blood Marker for Breast Cancer Miami, Florida BORIS (Brother of Regulator of Imprinting Sites) as a possible new Blood Marker for Breast Cancer RCS London

Now